My Friday's Pick is BIOSONICS (BISN) stock value has been beaten due to the co-founder and CEO's death Mr. Jack Paller. They have a wealth of knowledge with many FDA patents and revenues. A few days ago they had an average price of approx. .06 for many months.
Approx O/S 328 Million and FLoat 100 Million.
Bid:.023 Ask: .025
Here are some links:
Company Website- biosonics.com
Company Profile- biosonics.com
EDGAR Information-
sec.gov
SALITRON Dry mouth
biosonics.com
CYSTOTRON Incontinence
biosonics.com
MEGS Impotence
biosonics.com
Nasotron Sinus relief
biosonics.com
Company news - biosonics.com
Stock Research Analysis -
biosonics.com
Company email
biosonics@biosonics.com
Other DD:
The philosophy of our investment approach is based upon the "law of contrary reason", the ability to perceive what the masses and many of their gurus rarely sense-their failure to flout orthodox, non-rewarding fiscal practices. In recommending BIOSONICS, symbol BISN, on the Bulletin Board, approximate bid 6 cents, (there are 328,000,000 shares outstanding) we recognize that stock market prejudices are different to negate. To date, BISN has raised over $15,000,000 in development funds, focusing on electrotherapeutics and diagnostic devices to manage and treat intractable medical CONDITIONS, SUCH AS; DRY MOUTH, URINARY / FECAL INCONTINENCE, NASAL-SINUS CONGESTION, and IMPOTENCE. The company's non-invasive devices counteract these malfunctions with no adverse side effects).
BISN has received SIX PATENTS; and has FDA approval for the marketing of the Salitron (for dry mouth relief), Cystotron (for urinary incontinence), Anotron (for fecal incontinence) and the BIDDS Glove (a diagnostic tool to be used with the Cystotron and Anotron devices).
Since new drug development is cost prohibitive, the public is increasingly receptive to alternative means of treating body malfunctions. Biosonics, with its numerous applications, is establishing itself s as a leader in the field of electrotherapeutics treatments and as a standout for achieving success in its treatment methods).
BISN products are available by prescription only; to say that future earnings could exhibit, arithmetically progressing assets, earnings and revenues, could be, sheer understatement.
FUTURE
The company notes; "All of our products are noninvasive portable, battery operated electro-therapeutic devices designed for personal usage in the home environment. All products utilize the body's inherent process to stimulate the nerves or muscles required for the therapy, thereby causing a natural reaction. There have been no reported side effects from the usage of these products, since no drugs, surgery or other invasive treatments are utilized".
Other than existing products and systems, BISN is developing future products, among them a MEGS ? (Male Electronic Genital Stimulator) system. The MEGS is intended as a retraining device -for psychogenically impotent males. The MEGS works by- directly stimulating the nerves to the blood vessels of the #####. This starts the natural process that results, in an erection. Biosonics is the only company with a unique patented device to counteract impotence through the body's own natural erectile process. This US Patented device is in the final stages for FDA submittal.
NASOTRON ? SYSTEM. The Nasotron is intended to clear obstructed nasal-sinus passages, thereby countering, pollen responses and other allergies and postnasal problems without the use of drugs. This US Patented device is in the final stages for FDA submittal.
HUMAN
Historians have claimed, and we agree, that Uncle Sam's Medicare program, despite its flaws, is among the most "human" and pragmatic endeavors ever undertaken by civilized cultures. Few mortals, or even "Power Elitists", realize that prior to Medicare, 80% of personal bankruptcies in the United States were ignited by burdensome, debilitating medical bills.
BISN muses...... Biosonics has contacted Medicare for a re-review of its insurance reimbursement application for the Salitron device (FDA approved). While awaiting their decision, we are encouraged by the 35+ major, private insurance carriers who have reimbursed us for the Salitron System. This therapeutic device (which has approximately 200 prescribing doctors nationwide) could help the over I million Americans who suffer from dry mouth. At present, there is no other clinically approved therapy available to those afflicted with dry mouth, caused by Sjogren's Syndrome. The vast majority of patients are elderly Medicare recipients and approval would make the treatment more widely acceptable and affordable. Medicare approval would help the company to generate sufficient revenues to recoup the company's investment in the Salitron and provide a profit as well.
Since public awareness and acknowledgment of incontinence is ever-increasing and the demand for successful treatment methods is on the rise, Biosonics intends to market the Cystotron in 1998. Proven effective in counteracting urinary incontinence, this condition is caused primarily by childbirth which weakens the pelvic floor muscles. If the muscles are not toned or strengthened, each time a woman laughs, coughs or sneezes, she passes urine. This debilitative condition restricts women's activities, and many spend significant amounts of money on over-the-counter, non reimbursable diapers, deodorants and disinfectants. We plan to conduct a six month, 500 women market study on stress incontinence in early 1998, to further enhance acceptance."
In the U.S.(not overseas markets), 8 million women suffer from stress incontinence and the market currently consumes $20 billion. BISN's -goal is to sell 8 thousand devices in the year 1999 and ramp up to 80 thousand devices (I% of the market) by the year 2001. "A 1% market share would generate revenues in excess of $100 million and since no company currently dominates this market, we are confident we can claim our share".
Bionics is currently reviewing the international market for its product line. Due to the acceptance of electrother apeutics medical devices in Europe, BISN is optimistic that the show will produce several potential distributors. The successful marketing of the Salitron and Systotron along with the greater acceptance in the international market place are just some of the components which will prove profitable for Biosonics".
BABY BOOMERS
BISN writes, "we plan to finalize our testing of the MEGS? (male impotence) and , Nasotron? (nasavsinus decongestant) for FDA submission. Both of these markets are large and these products, upon successful introduction, will substantially increase our sales and profits. Many believe that as'many as 20 million men in the US are afflicted -by impotence and to our knowledge, the MEGS is the only device being developed that will restore function by using the body's natural resources through retraining. The 'MEGS require no surgery, implantation, drugs, injections or other unnatural means and to date, no adverse side effects have been noted. A 1% market share would produce revenues in excess of $300 million and the profitability of the much larger world market is obvious.
The Nasotron performs as an electronic antihistamine by clearing the nasal/sinus passageways and drying up runny noses, but causes'no side effects. 'Mere are over 80 million people in the US who suffer from nasavsinus congestion and most are using either over-the-counter or prescription drugs for relief. Unlike the Nasotron, most (if not all) of these remedies have varying degrees of adverse side effects. A 1% market share would produce revenues in excess of $ 100 million and the profitability of the much larger world market is obvious.
There are many more applications of BISN technology both in diagnostic capacities as well as therapeutic treatments which counteract malfunctions which commonly occur in aging populations. If you believe, as we do, that electrotherapy is a viable, effective alternative to high-priced drugs with severe side effects, then Biosonics is a leader worth following ... for investors, employees and patients in need of this technology. Our research shows that as "Baby Boomers" age, previously quoted numbers for respective diseases will increase. This market is ready for natural therapies that work with their body enabling them to stay not only active, but healthy as well".
Prospective products include ...
VAGITRON ?- This is a device designed to stimulate vaginal secretions in women with vaginal secretary deficiencies and to assist in normal sexual function. This device also counteracts female anorgasmia.
IMMUNOTRON? - The IMMUNOTRON is a device designed to influence the cerebral nervous system which in turn will activate the body's immune system.
CANCER TUMOR REDUCTION - This is a device intended to reduce cancerous cells in certain tumors in conjunction with chemotherapy.
WOUND HEALER - This device is designed to accelerate wound healing by stimulating cell migration.
POLITICIAN
As an "R&D" entity, BISN's balance sheet and income statements have less relevancy, at this time, than a Politicians promise.
It may not stun our sages I if a Corporate Casanova covets BISN; possibly paying a premium price to acquire or joint venture with the company. The paths to glory, for an emerging equity can be paved with fiscal minefields, with "miscarriages of expectations". BISN may be inoculated against "the slings and arrows of outrageous fortune", by virtue of their myriad products unlike the plethora of callow corporations that are dependent upon one or two products, hoping to build a' "better mousetrap".
A cynic has suggested that if you build a better mousetrap, someone else will "build a bigger mouse,".
BISN may defy the cynical observation.
Buy with the risk capital, and be patient; cognizant of the fact that virtually every major medical health corporation; was initially nurtured by a small cadre of "believers"; who defied the "prosaic"; ultimately spawning a cornucopia of blessings for both the public and their shareholders.
Best wishes:) |
